The GV-backed cardiovascular therapeutics company has priced an upsized offering on Nasdaq, with the shares closing just marginally higher on the first day.

Tenaya Therapeutics, a US-based heart disease therapy developer leveraging research from University of Texas Southwestern Medical Center and Gladstone Institutes, listed in a $180m initial public offering on the Nasdaq Global Select Market on Thursday.
The offering involved the company issuing 12 million shares at $15 each, in the middle of the $14 to $16 range, and they opened at $19.50 apiece prior to closing at $15.35 on the first day of trading.
Founded in 2016, Tenaya…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
email
Linked in